A LEADER IN SPECIALTY CARE

Transcription

1 A LEADER IN SPECIALTY CARE Zi Qing, Pompe Disease, Taiwan

2 SCIENCE-DRIVEN, PATIENT-FOCUSED Patients and science are at the center of everything we do, defining and uniting our efforts across rare diseases, multiple sclerosis, oncology and immunology. A LEADER IN SPECIALTY CARE Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, oncology and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Our ambition is to be the industry leader in specialty care. We currently provide more than 20 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories. BUILDING ON A STRONG LEGACY Our approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, we rapidly grew to become one of the world s leading biotechnology companies, recognized for our pioneering development of treatments for rare genetic disorders and our innovative contributions to medical science and biomanufacturing. Genzyme became part of Sanofi in While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi s programs in oncology and immunology. Our new name Sanofi Genzyme reflects the expansion of our scope and our close integration within Sanofi. Inspired by the potential to improve patients lives, more than 3,000 Sanofi Genzyme employees work at the forefront of health care and biotechnology, supported by thousands of Sanofi colleagues around the world Science Center, Framingham, MA, USA FOUNDED AS GENZYME Focused on rare diseases GENZYME ACQUIRED BY SANOFI Expanded focus to include multiple sclerosis BECAME SANOFI GENZYME Specialty care global business unit Expanded focus to include oncology and immunology

3 AN INNOVATOR IN RARE DISEASES A LEADER IN MULTIPLE SCLEROSIS Kaitie, MPS I Disease, Australia Tiger, Multiple Sclerosis, United Kingdom Over the past three decades, we pioneered research and development for patients with rare genetic conditions including Gaucher, Fabry, MPS I and Pompe diseases, as well as certain thyroid cancers. We work to improve the diagnosis of rare diseases through physician education, awareness programs and support of testing and screening initiatives. In addition to internal research and development, we have formed several partnerships to help us develop new treatment options for rare diseases, including collaborations with Alnylam Pharmaceuticals and Voyager Therapeutics. We are committed to empowering the lives of patients with rare diseases by offering sustainable, transformative healthcare options. Since 2011, we have rapidly emerged as a leader in multiple sclerosis (MS), an often disabling disease of the central nervous system affecting more than 2.3 million people worldwide. We have introduced treatments that provide additional therapeutic options for patients, and established partnerships with MS physicians, advocates and researchers. Through the work of scientists in our labs and collaborative efforts with research partners, we are focused on developing novel treatments that seek to go beyond what existing MS therapies offer.

4 RESEARCHING NEW TREATMENTS IN IMMUNOLOGY A RENEWED COMMITMENT IN ONCOLOGY Donna, Rheumatoid Arthritis, USA James, Prostate Cancer, USA Immunology is an area of growth for Sanofi Genzyme and an area in which we hope to make a significant difference in patients lives. In collaboration with Regeneron, we have brought two new therapies to market. The first of these is for the treatment of moderate to severe rheumatoid arthritis, a chronic and painful inflammatory disorder that damages the joints. The second is approved for the treatment of adults with moderate to severe atopic dermatitis, a chronic inflammatory skin disease and the most common form of eczema.* We are continuing to study other allergic and respiratory diseases, including asthma, nasal polyposis and eosinophilic esophagitis. *in the U.S. only The need for new cancer medicines remains great, and we are committed to helping to address this need. Sanofi has a strong heritage in oncology and has laid out a strategy to re-establish itself as a leader in cancer treatment. Now as part of Sanofi Genzyme, we are concentrating on building our oncology business in areas such as prostate cancer where we have a significant presence and currently provide important options for patients. We also have a special focus on the promising field of immuno-oncology in which a patient s immune system is used to fight cancer cells. We are building a pipeline of potential treatments based on this approach through partnerships with researchers and other companies.

5 SCIENCE Sanofi has a strong pipeline with a significant portion of its R&D spending concentrated on specialty care. Sanofi Genzyme s presence in Cambridge, Massachusetts the international center for biotechnology and innovation has helped Sanofi expand its capacity to collaborate with world-class scientists in universities, research hospitals, and other companies to accelerate treatment development. R&D PIPELINE HIGHLIGHTS NASAL POLYPS Dupilumab^ Phase 3 ASTHMA Dupilumab^ Phase 3 hattr AMYLOIDOSIS Patisiran* Phase 3 POMPE DISEASE NeoGAA Phase 3 MULTIPLE MYELOMA Isatuximab Phase 3 ACID SPHINGOMYELINASE DEFICIENCY (ASMD) Olipudase Alfa Phase 2 EOSINOPHILIC ESOPHAGITIS Dupilumab^ Phase 2 UVEITIS Sarilumab^ Phase 2 FABRY DISEASE Oral GCS Inhibitor Phase 2 GAUCHER DISEASE TYPE 3 Oral GCS Inhibitor Phase 2 PARKINSON S DISEASE WITH A GBA MUTATION Oral GCS Inhibitor Phase 2 CUTANEOUS SQUAMOUS CELL CARCINOMA PD-1 Inhibitor^ Phase 2 HEMOPHILIA Fitusiran* Phase 2 MULTIPLE SCLEROSIS GLD52 (GZ402668) Phase 1 * being developed with Alnylam ^ being developed with Regeneron denotes a phase 2/3 trial The agents mentioned here are investigational and have not yet been approved. Science Center, Framingham, MA, USA

6 COMMUNITY Universal Access Community Boating, Boston, MA, USA We believe in having a lasting, positive impact where our employees live and work. Through a combination of financial contributions and employee involvement, we build sustainable partnerships with schools and nonprofit organizations. We develop and fund innovative science education programs for people of all ages. We also fund community-based, nonprofit organizations dedicated to health and increasing access to health care, and other critical community needs. BILL SIBOLD Executive Vice President and Head of Sanofi Genzyme WE HAVE TO BE FOCUSED ON THE SCIENCE, FOCUSED ON THE PATIENTS THAT IS THE CORE OF WHAT WE DO. IF WE DO THAT RIGHT, WE CAN ULTIMATELY BE SUCCESSFUL. RESPONSIBILITY ABOUT SANOFI ABOUT SANOFI GENZYME Ailin, Gaucher Disease, Cuba Our dedication to patients extends beyond the development of medicines. We support access to treatment through humanitarian programs to help ensure that appropriate treatment reaches all those who need it. Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients needs. Sanofi is organized into five global business units: Sanofi Genzyme, Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Pasteur and Consumer Healthcare. Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. > Based in Cambridge, MA, USA > 3,000+ employees globally > Revenues of 5B > Based in Paris, France > Present in more than 100 countries > 110,000 employees globally > Revenues of 33B > 5.2B annual investment in R&D

7 2017 Genzyme Corporation. All rights reserved. SAGLB.GZ /2017